Literature DB >> 16501076

Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.

Michele Di Mascio1, Irini Sereti, Lynn T Matthews, Ven Natarajan, Joseph Adelsberger, Richard Lempicki, Christian Yoder, Elizabeth Jones, Catherine Chow, Julia A Metcalf, Igor A Sidorov, Dimiter S Dimitrov, Michael A Polis, Joseph A Kovacs.   

Abstract

Both naïve CD4+ and naïve CD8+ T cells are depleted in individuals with human immunodeficiency virus type 1 (HIV-1) infection by unknown mechanisms. Analysis of their dynamics prior to and after highly active antiretroviral therapy (HAART) could reveal possible mechanisms of depletion. Twenty patients were evaluated with immunophenotyping, intracellular Ki67 staining, T-cell receptor excision circle (TREC) quantitation in sorted CD4 and CD8 cells, and thymic computed tomography scans prior to and approximately 6 and approximately 18 months after initiation of HAART. Naïve T-cell proliferation decreased significantly during the first 6 months of therapy (P < 0.01) followed by a slower decline. Thymic indices did not change significantly over time. At baseline, naïve CD4+ T-cell numbers were lower than naive CD8+ T-cell numbers; after HAART, a greater increase in naïve CD4+ T cells than naïve CD8+ T cells was observed. A greater relative change (n-fold) in the number of TREC+ T cells/mul than in naïve T-cell counts was observed at 6 months for both CD4+ (median relative change [n-fold] of 2.2 and 1.7, respectively; P < 0.01) and CD8+ T cell pools (1.4 and 1.2; P < 0.01). A more pronounced decrease in the proliferation than the disappearance rate of naïve T cells after HAART was observed in a second group of six HIV-1-infected patients studied by in vivo pulse labeling with bromodeoxyuridine. These observations are consistent with a mathematical model where the HIV-1-induced increase in proliferation of naïve T cells is mostly explained by a faster recruitment into memory cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501076      PMCID: PMC1395465          DOI: 10.1128/JVI.80.6.2665-2674.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection.

Authors:  Z Q Zhang; D W Notermans; G Sedgewick; W Cavert; S Wietgrefe; M Zupancic; K Gebhard; K Henry; L Boies; Z Chen; M Jenkins; R Mills; H McDade; C Goodwin; C M Schuwirth; S A Danner; A T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 2.  HIV-1 and the thymus.

Authors:  G N Gaulton; J V Scobie; M Rosenzweig
Journal:  AIDS       Date:  1997-03-15       Impact factor: 4.177

3.  Human naive T cells activated by cytokines differentiate into a split phenotype with functional features intermediate between naive and memory T cells.

Authors:  D Unutmaz; F Baldoni; S Abrignani
Journal:  Int Immunol       Date:  1995-09       Impact factor: 4.823

4.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen.

Authors:  N Sachsenberg; A S Perelson; S Yerly; G A Schockmel; D Leduc; B Hirschel; L Perrin
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

6.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

7.  IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation.

Authors:  Irini Sereti; Kara B Anthony; Hector Martinez-Wilson; Richard Lempicki; Joseph Adelsberger; Julia A Metcalf; Claire W Hallahan; Dean Follmann; Richard T Davey; Joseph A Kovacs; H Clifford Lane
Journal:  Blood       Date:  2004-04-13       Impact factor: 22.113

8.  CD8 naive T cell counts decrease progressively in HIV-infected adults.

Authors:  M Roederer; J G Dubs; M T Anderson; P A Raju; L A Herzenberg; L A Herzenberg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.

Authors:  S Fleury; R J de Boer; G P Rizzardi; K C Wolthers; S A Otto; C C Welbon; C Graziosi; C Knabenhans; H Soudeyns; P A Bart; S Gallant; J M Corpataux; M Gillet; P Meylan; P Schnyder; J Y Meuwly; W Spreen; M P Glauser; F Miedema; G Pantaleo
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Antigen-independent activation of naive and memory resting T cells by a cytokine combination.

Authors:  D Unutmaz; P Pileri; S Abrignani
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  33 in total

Review 1.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Authors:  Jessica N Hodge; Sharat Srinivasula; Zonghui Hu; Sarah W Read; Brian O Porter; Insook Kim; Joann M Mican; Chang Paik; Paula Degrange; Michele Di Mascio; Irini Sereti
Journal:  Blood       Date:  2011-07-21       Impact factor: 22.113

3.  Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes.

Authors:  Sharat Srinivasula; Richard A Lempicki; Joseph W Adelsberger; Chiung-Yu Huang; Joshua Roark; Philip I Lee; Adam Rupert; Randy Stevens; Irini Sereti; H Clifford Lane; Michele Di Mascio; Joseph A Kovacs
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

4.  A novel anti-HIV immunotherapy to cure HIV.

Authors:  Ali Ahmad; Charles R Rinaldo
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

5.  A mechanistic model for bromodeoxyuridine dilution naturally explains labelling data of self-renewing T cell populations.

Authors:  Vitaly V Ganusov; Rob J De Boer
Journal:  J R Soc Interface       Date:  2012-11-08       Impact factor: 4.118

6.  Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging.

Authors:  Douglas A Bazdar; Magdalena Kalinowska; Scott F Sieg
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

7.  Cycling memory CD4+ T cells in HIV disease have a diverse T cell receptor repertoire and a phenotype consistent with bystander activation.

Authors:  Wei Jiang; Souheil-Antoine Younes; Nicholas T Funderburg; Joseph C Mudd; Enrique Espinosa; Miles P Davenport; Denise C Babineau; Scott F Sieg; Michael M Lederman
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  The contribution of the thymus to the recovery of peripheral naive T-cell numbers during antiretroviral treatment for HIV infection.

Authors:  Ruy M Ribeiro; Rob J de Boer
Journal:  J Acquir Immune Defic Syndr       Date:  2008-09-01       Impact factor: 3.731

9.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

10.  Quantifying T lymphocyte turnover.

Authors:  Rob J De Boer; Alan S Perelson
Journal:  J Theor Biol       Date:  2013-01-09       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.